QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.104.010165v1 67/6/1909    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Parker, R. A. Articles by Noor, M. A. Search for Related Content PubMed PubMed Citation Articles by Parker, R. A. Articles by Noor, M. A.

Endoplasmic Reticulum Stress Links Dyslipidemia to Inhibition of Proteasome Activity and Glucose Transport by HIV Protease Inhibitors

Metabolic and Cardiovascular Discovery Biology (R.A.P., S.W.), Discovery Toxicology (O.P.F., R.M., C.E., F.W.), Applied Genomics (W.F., W.-P.Y.), and Virology Medical Affairs (M.A.N.), Bristol-Myers Squibb Pharmaceutical Research Institute, Pennington, New Jersey

The lipid and metabolic disturbances associated with human immunodeficiency virus (HIV) protease inhibitor therapy in AIDS have stimulated interest in developing new agents that minimize these side effects in the clinic. The underlying explanation of mechanism remains enigmatic, but a recently described link between endoplasmic reticulum (ER) stress and dysregulation of lipid metabolism suggests a provocative integration of existing and emerging data. We provide new evidence from in vitro models indicating that proteasome inhibition and differential glucose transport blockade by protease inhibitors are proximal events eliciting an ER stress transcriptional response that can regulate lipogenic pathways in hepatocytes or adipocytes. Proteasome activity was inhibited in vitro by several protease inhibitors at clinically relevant (micromolar) levels. In the intact cells, protease inhibitors rapidly elicited a pattern of gene expression diagnostic of intracellular proteasome inhibition and activation of an ER stress response. This included induction of transcription factors GADD153, ATF4, and ATF3; amino acid metabolic enzymes; proteasome components; and certain ER chaperones. In hepatocyte lines, the ER stress response was closely linked to moderate increases in lipogenic and cholesterogenic gene expression. However, in adipocytes where GLUT4 was directly inhibited by some protease inhibitors, time-dependent suppression of lipogenic genes and triglyceride synthesis was observed in coordination with the ER stress response. These results further link ER stress to dyslipidemia and contribute to a unifying mechanism for the pathophysiology of protease inhibitor-associated lipodystrophy, helping explain differences in clinical metabolic profiles among protease inhibitors.

Address correspondence to: Dr. Rex A. Parker, Metabolic and Cardiovascular Discovery Biology, Bristol-Myers Squibb Pharmaceutical Research Institute,311Pennington-RockyHillRd.,Pennington,NJ08534.E-mail: rex.parker{at}bms.com

This article has been cited by other articles:

				J. E. Mallewa, E. Wilkins, J. Vilar, M. Mallewa, D. Doran, D. Back, and M. Pirmohamed HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options J. Antimicrob. Chemother., June 18, 2008; (2008) dkn251v1. [Abstract] [Full Text] [PDF]

				J. A. Perez-Molina, P. Domingo, E. Martinez, and S. Moreno The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy J. Antimicrob. Chemother., May 14, 2008; (2008) dkn191v1. [Abstract] [Full Text] [PDF]

				P. C. LaRosa, J.-J. M. Riethoven, H. Chen, Y. Xia, Y. Zhou, M. Chen, J. Miner, and M. E. Fromm Trans-10, cis-12 conjugated linoleic acid activates the integrated stress response pathway in adipocytes Physiol Genomics, November 14, 2007; 31(3): 544 - 553. [Abstract] [Full Text] [PDF]

				D. Ucar, I. Neuhaus, P. Ross-MacDonald, C. Tilford, S. Parthasarathy, N. Siemers, and R.-R. Ji Construction of a reference gene association network from multiple profiling data: application to data analysis Bioinformatics, October 15, 2007; 23(20): 2716 - 2724. [Abstract] [Full Text] [PDF]

				M. F. Gregor and G. S. Hotamisligil Thematic review series: Adipocyte Biology. Adipocyte stress: the endoplasmic reticulum and metabolic disease J. Lipid Res., September 1, 2007; 48(9): 1905 - 1914. [Abstract] [Full Text] [PDF]

				J. J. Gills, J. LoPiccolo, J. Tsurutani, R. H. Shoemaker, C. J.M. Best, M. S. Abu-Asab, J. Borojerdi, N. A. Warfel, E. R. Gardner, M. Danish, et al. Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo Clin. Cancer Res., September 1, 2007; 13(17): 5183 - 5194. [Abstract] [Full Text] [PDF]

				M. Guffanti, A. Caumo, L. Galli, A. Bigoloni, A. Galli, G. Dagba, A. Danise, L. Luzi, A. Lazzarin, and A. Castagna Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects Eur. J. Endocrinol., April 1, 2007; 156(4): 503 - 509. [Abstract] [Full Text] [PDF]

				S. De Barros, A. Zakaroff-Girard, M. Lafontan, J. Galitzky, and V. Bourlier Inhibition of Human Preadipocyte Proteasomal Activity by HIV Protease Inhibitors or Specific Inhibitor Lactacystin Leads to a Defect in Adipogenesis, Which Involves Matrix Metalloproteinase-9 J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 291 - 299. [Abstract] [Full Text] [PDF]

				H. Zhou, E. C. Gurley, S. Jarujaron, H. Ding, Y. Fang, Z. Xu, W. M. Pandak Jr., and P. B. Hylemon HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes Am J Physiol Gastrointest Liver Physiol, December 1, 2006; 291(6): G1071 - G1080. [Abstract] [Full Text] [PDF]

				H. Zhou, W. M. Pandak Jr., V. Lyall, R. Natarajan, and P. B. Hylemon HIV Protease Inhibitors Activate the Unfolded Protein Response in Macrophages: Implication for Atherosclerosis and Cardiovascular Disease Mol. Pharmacol., September 1, 2005; 68(3): 690 - 700. [Abstract] [Full Text] [PDF]